IDENTIFICATION OF POTENTIALLY NEUROTOXIC PYRIDINIUM METABOLITE IN THE URINE OF SCHIZOPHRENIC-PATIENTS TREATED WITH HALOPERIDOL

被引:82
|
作者
SUBRAMANYAM, B
POND, SM
EYLES, DW
WHITEFORD, HA
FOUDA, HG
CASTAGNOLI, N [1 ]
机构
[1] VIRGINIA POLYTECH INST & STATE UNIV, DEPT CHEM, BLACKSBURG, VA 24061 USA
[2] UNIV QUEENSLAND, PRINCESS ALEXANDRA HOSP, DEPT MED, WOOLLOONGABBA, QLD 4102, AUSTRALIA
[3] WOLSTON PK HOSP, CLIN STUDIES UNIT, WACOL, QLD 4076, AUSTRALIA
关键词
D O I
10.1016/0006-291X(91)91228-5
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Evidence that the parkinsonian inducing agent MPTP is biotransformed to a pyridinium species that selectively destroys nigrostriatal neurons in humans and subhuman primates has prompted studies to evaluate the metabolic fate of the structurally related neuroleptic agent haloperidol. With the aid of a highly sophisticated atmospheric pressure ionspray HPLC/MS/MS assay, unambiguous evidence has been obtained for the presence of the haloperidol pyridinium species in extracts of urine obtained from haloperidol-treated patients and in extracts of NADPH-supplemented human liver microsomal incubation mixtures containing haloperidol. The potential significance of the formation of this putative neurotoxic pyridinium species is considered. © 1991.
引用
收藏
页码:573 / 578
页数:6
相关论文
共 50 条
  • [1] IDENTIFICATION OF A POTENTIALLY NEUROTOXIC PYRIDINIUM METABOLITE OF HALOPERIDOL IN RATS
    SUBRAMANYAM, B
    ROLLEMA, H
    WOOLF, T
    CASTAGNOLI, N
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1990, 166 (01) : 238 - 244
  • [2] STUDIES ON THE INVITRO CONVERSION OF HALOPERIDOL TO A POTENTIALLY NEUROTOXIC PYRIDINIUM METABOLITE
    SUBRAMANYAM, B
    WOOLF, T
    CASTAGNOLI, N
    CHEMICAL RESEARCH IN TOXICOLOGY, 1991, 4 (01) : 123 - 128
  • [3] DETECTION OF A NEUROTOXIC QUATERNARY PYRIDINIUM METABOLITE IN THE LIVER OF HALOPERIDOL-TREATED RATS
    ABLORDEPPEY, SY
    BORNE, RF
    PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1993, 46 (03) : 739 - 744
  • [4] PLASMA REDUCED HALOPERIDOL/HALOPERIDOL RATIOS IN SCHIZOPHRENIC-PATIENTS TREATED WITH HIGH DOSAGES OF HALOPERIDOL
    CHANG, WH
    SHIEH, YS
    LIU, HC
    JANN, MW
    CHIEN, CP
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 1994, 4 (02) : 119 - 126
  • [5] PHARMACOKINETICS OF HALOPERIDOL AND HALOPERIDOL DECANOATE IN SCHIZOPHRENIC-PATIENTS
    NAYAK, RK
    NAIR, NPV
    DOOSE, DR
    MCCARTHY, LR
    DESIRAJU, RK
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1985, 37 (02) : 217 - 217
  • [6] Empirical and molecular modeling study of the pyridinium species RHPP+, an abundant and potentially neurotoxic metabolite of haloperidol
    Ooms, F
    Delvosal, S
    Wouters, J
    Durant, F
    Dockendolf, G
    Van't Land, C
    Glass, T
    Castagnoli, N
    Van der Schyf, CJ
    JOURNAL OF THE CHEMICAL SOCIETY-PERKIN TRANSACTIONS 2, 2000, (09): : 1781 - 1787
  • [7] PHARMACODYNAMICS AND PHARMACOKINETICS OF HALOPERIDOL AND REDUCED HALOPERIDOL IN SCHIZOPHRENIC-PATIENTS
    CHANG, WH
    LIN, SK
    JANN, MW
    LAM, YWF
    CHEN, TY
    CHEN, CT
    HU, WH
    YEH, EK
    BIOLOGICAL PSYCHIATRY, 1989, 26 (03) : 239 - 249
  • [8] KETONE REDUCTASE-ACTIVITY AND REDUCED HALOPERIDOL HALOPERIDOL RATIOS IN HALOPERIDOL-TREATED SCHIZOPHRENIC-PATIENTS
    HUANG, HF
    JANN, MW
    TSENG, YT
    CHUNG, MC
    CHIEN, CP
    CHANG, WH
    PSYCHIATRY RESEARCH, 1995, 57 (02) : 101 - 108
  • [9] LITHIUM COMBINED WITH HALOPERIDOL IN SCHIZOPHRENIC-PATIENTS
    LERNER, Y
    MINTZER, Y
    SCHESTATZKY, M
    BRITISH JOURNAL OF PSYCHIATRY, 1988, 153 : 359 - 362
  • [10] PROLACTIN RESPONSES TO HALOPERIDOL IN DRUG-FREE AND TREATED SCHIZOPHRENIC-PATIENTS
    MARKIANOS, M
    SAKELLARIOU, G
    BISTOLAKI, E
    JOURNAL OF NEURAL TRANSMISSION-GENERAL SECTION, 1991, 83 (1-2) : 37 - 42